ABBV (NYSE) - AbbVie | Stock Price & Analysis
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00287Y1091
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Web URL:
Classification
Market Cap in USD | 251,395m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2013-01-02 |
Ratings
Fundamental | 5.38 |
Dividend | 9.01 |
Performance 5y | 5.98 |
Rel. Performance vs Sector | 1.84 |
Analysts | 3.83 |
Fair Price Total Ret. | 144.53 |
Fair Price DCF | todo |
Technical
Growth TTM | -8.34% |
CAGR 5y | 13.91% |
CAGR / Mean Drawdown | 1.54 |
Sharpe Ratio TTM | -0.69 |
Alpha vs SP500 TTM | -19.21 |
Beta vs SP500 5y weekly | 0.66 |
CAPM | 7.05% |
Average Daily Range 2m | 1.73% |
Reversal Oscillator | 63.86 |
Volatility GJR Garch 1y | 23.42% |
Price / SMA 50 | -1.15% |
Price / SMA 200 | -1.68% |
Current Volume | 9297.4k |
Average Volume 20d | 5359.1k |
Dividends
Yield TTM | 4.16% |
Yield on Cost 5y | 7.98% |
Dividends CAGR 5y | 9.46% |
Consistency of Dividends all time | 100.0% |